FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Zidavi is recommended by the Infectious Disease Society of America
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
Subscribe To Our Newsletter & Stay Updated
